Seattle-based Kineta, the company developing drugs against autoimmune diseases, said today it has formed an alliance with MPI Research. Terms of the deal weren’t disclosed, but Kineta will get support for animal studies that will enable it to start clinical trials in 2010, the company said. Kineta also received the second year of funding under a grant from the National Institutes of Health to advance its antiviral research program. We profiled Kineta and its unusual strategy back in July when it acquired drug candidates for multiple sclerosis and other autoimmune disorders.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
